Content
Executive Summary 4
1. Business environment 6
1.1 Macroeconomic situation 6
1.2 Legal framework 10
1.3 Trade agreements 19
2. Pharmaceutical Industry Overview 26
2.1 Global Pharmaceutical Industry 26
2.1.1 Production - Consumption 27
2.1.2 Export – Import 30
2.1.3Production and Consumption Situation in major
countries31
2.1.4 Large Enterprises in the world 35
2.2 Vietnam Pharmaceutical Industry Overview 37
2.2.1 History of Vietnam Pharmaceutical Industry 38
2.2.2 Industry Position 39
2.2.3 Industry Scale and Feature 40
2.2.4 Value Chain of Vietnam Pharmaceutical Industry 43
2.2.5 Raw Materials 44
2.2.6 Production technology 47
2
2.2.7 R&D 49
2.2.8 Production 50
2.2.9 Consumption 53
2.2.10 Export - Import 62
2.2.11 Price movement 66
2.2.12 Distribution system 69
2.3 Risks and challenges 75
2.4 Industry planning 82
2.5 Driving forces and forecast 84
3. Enterprise analysis 94
3.1 Profitability 97
3.2 Cost structure 100
3.3 Asset Management Ratios 104
3.4 Capital Structure 108
3.5 Solvency 110
3.6 Return on Investment 112
4. Appendix of Financial statements 114
3
ETC Ethical drugs
EU-GMP Europe Good Manufacturing Practice
EVFTA EU – Vietnam Free Trade Agreement
GDP Good Distribution Practice
Generic Drug
Drug product that is comparable to a brand/reference
listed drug product in dosage form, strength, quality
and performance characteristics, and intended use."
GLP Good Laboratory Practice
GMP Good Manufacturing Practice
GMP - WHOGood Manufacturing Practice recommended by the
World Health Organization (WHO - GMP)
GPP Good Pharmacy Practice
GSP Good Storage Practice
Abbreviations
OTC Over The Counter (nonprescription-drugs)
Patent Drug Drugs under intellectual property rights
Pharmerging Countries with emerging Pharmaceutical Industry
PIC/S - GMPPharmaceutical Inspection Co-operation Scheme on Good
Manufacturing Practice (EU-GMP)
GDC General Department of Vietnam Custom
GSO General Statistic Office of Vietnam
TPP Trans-Pacific Partnership
WHO World Health Organization
WTO World Trade Organization
MOH Ministry of Health
DAV Drug Administration of Vietnam
4
Executive Summary
There are about 153 western medicines producing
enterprises, 80 traditional medicines producing
enterprises, and over 300 establishments
producing traditional medicines in 2015.
Vietnam's pharmaceutical sector uses about
60,000 tons of pharmaceuticals, including 80-
90% of imported pharmaceuticals.
The growth of the prescription drug market will
exceed the growth rate of Over-the-counter
(OTC) market
According to the Drug Administration of
Vietnam - Ministry of Health, the number of
drug items re-declared price as of 2/9/2018: the
number of drug items with fluctuating price
increase/decrease occupy very little (about
0.026%) of the total commercially available
drugs
Content is intentionally removed for demo purpose
5
Executive Summary
The biggest wholesale market systems in
Vietnam pharmaceutical distribution in Ho Chi
Minh City and Hanoi.
Pharmaceutical products are necessities, thus,
economic growth virtually has hardly any
impact on the industry growth rate,
For the WTO, the Vietnamese pharmaceutical
market has gradually opened
M&A trend between domestic and foreign
enterprises takes place strongly in the form of
franchise drug production and the field of
distribution.
Most of the enterprises of pharmaceutical
industry maintained positive operation with
high levels of gross profit and net profit in the
period 2015-2016
Content is intentionally removed for demo purpose
6
1. Business environment
1.1 Macroeconomic situation
1.2 Legal framework
1.3 Trade agreements
Content
7
1. Business environment
1.1 Macroeconomic situation
GDP growth, 2011 – 3M/2018• GDP in the first three months of 2018 was estimated to increase by 7.38%
over the same period last year, the highest increase in the first quarter of
10 years.
Source: VIRAC, GSO
Source: VIRAC, GSO
Unit: %
Consumer Price Index for Medicines and Health Services, 2012 - 3M/2018
Content is intentionally removed for demo purpose
8
1. Business environment
1.1 Macroeconomic situation
Source: VIRACSource: VIRAC, SBV
VND/USD exchange rate, 3/2016 - 3/2018 VND/CNY exchange rate, 2016 – 3/2018
Content is intentionally removed for demo purpose
9
The pharmaceutical market has a lot of potential when the
demand for medicines is always increasing
1. Business environment
1.1 Macroeconomic situation
Source: VIRAC, GSO
Population and population growth, 2006 -2017
Million people
Source: VIRAC, GSO
Population structure, 1999 - 2016 Content is intentionally removed for demo purpose
10
1. Business environment
1.1 Macroeconomic situation
1.2 Legal framework
1.3 Trade agreements
Content
11
1. Business environment
1.2 Legal framework
Regulations on standards of Pharmaceutical Industry
Content is intentionally removed for demo purpose
12
1. Business environment
1.2 Legal framework
Content is intentionally removed for demo purpose
Regulations on drug registration
Regulations on control of drug prices
13
1. Business environment
1.2 Legal framework
Content is intentionally removed for demo purpose
Regulations on import-export
Regulations on drug advertising information
14
1. Business environment
1.2 Legal framework
Content is intentionally removed for demo purpose
Regulations on drug promotion
Distribution
Bidding
15
1. Business environment
1.2 Legal framework
Content is intentionally removed for demo purposeRegulations on importing pharmaceutical materials
19
1. Business environment
1.1 Macroeconomic situation
1.2 Legal framework
1.3 Trade agreements
Content
1. Business environment
1.3 Trade agreements
20
1.3.1. WTO - Vietnam became the 150th member of WTO on 11/07/2006
Source: VIRAC, GDVC
Pharmaceuticals imports ,2012 – 3M/2018e
USD million
Content is intentionally removed for demo purpose
23
1.3.2 CPTPP - Comprehensive and Progressive Agreement for Trans-Pacific Partnership, was signed in Chile
1. Business environment
1.3 Trade agreements
Content is intentionally removed for demo purpose
25
1.3.3 Other trade agreements
1. Business environment
1.3 Trade agreements
Content is intentionally removed for demo purpose
26
2. Pharmaceutical Industry Overview
2.1 Global Pharmaceutical Industry
2.2 Vietnam Pharmaceutical Industry Overview
2.3 Risks and challenges
2.4 Industry planning
2.5 Driving forces and forecast
Content
27
In the period of 2010 - 2016, global drug spending increased at a CAGR of
4.6% per year from USD 888.2 billion in 2010 to USD 1,163.6 billion in
2016.
2. Pharmaceutical Industry Overview
2.1 Global Pharmaceutical Industry – 2.1.1 Production – Consumption
Source: VIRAC, IMS health
Global spending on medicines, 2010 - 2016e
Content is intentionally removed for demo purpose
28
Source: VIRAC, EvaluatePharma
2. Pharmaceutical Industry Overview
2.1 Global Pharmaceutical Industry – 2.1.1 Production – Consumption
Source: VIRAC, IMS health
Consumption structure by types of medicines, 2011 - 2016World sales of prescription drugs, 2010 - 2016
USD billion
Content is intentionally removed for demo purpose
29
World’s top 10 consumed phamaceuticals, 2016
Source: VIRAC, IMS health
Source: VIRAC, IMS health
2. Pharmaceutical Industry Overview
2.1 Global Pharmaceutical Industry – 2.1.1 Production – Consumption
USD billion
Consumption market share by group, 2016
Content is intentionally removed for demo purpose
30
Global pharmaceutical trade tended to decrease slightly in 2015
Export 2016 2017 Growth
Pharmaceuticals exporters, 2017
Source: VIRAC, Trademap
2. Pharmaceutical Industry Overview
2.1 Global Pharmaceutical Industry – 2.1.2 Export - Import
Source: VIRAC, UN Comtrade, Trademap
Source: VIRAC, UN Comtrade, Trademap
2016Value
(USD billion)2017
Value
(USD billion)
Pharmaceuticals importers, 2017
*HS: 3001 - 3004
*HS: 3003 - 3004 *HS: 3003 - 3004
Global pharmaceutical exports, 2010 - 2017e
USD billion
Content is intentionally removed for demo purpose
31
2. Pharmaceutical Industry Overview
2.1 Global Pharmaceutical Industry – 2.1.3 Typical countries
1. The U.SGeneral information about the healthcare industry of The U.S,
2016e
Total health expenditure
Government's health
expenditure
OOP expenses
Medicines spending per
capita
Import
Export
Source: VIRAC, OECD
Content is intentionally removed for demo purpose
32
2. Pharmaceutical Industry Overview
2.1 Global Pharmaceutical Industry – 2.1.3 Typical countries
2. Japan
Source: VIRAC, OECD
General information about the healthcare industry of Japan,
2016e
Total health expenditure
Government's health
expenditure
OOP expenses
Medicines spending per
capita
Import
Export
Content is intentionally removed for demo purpose
33
2. Pharmaceutical Industry Overview
2.1 Global Pharmaceutical Industry – 2.1.3 Typical countries
General information about the healthcare industry of China,
2016e
Total health expenditure
Total sales
Import
Export
3. China
Source: VIRAC, OECD
Source: VIRAC, CEIC Data
CNY billion
* Revenue includes: chemical drugs, biopharmaceuticals, oriental medicines and
medicinal herbs
Revenue of China’s pharmaceutical industry, 2012 - 2016
Content is intentionally removed for demo purpose
34
2. Pharmaceutical Industry Overview
2.1 Global Pharmaceutical Industry – 2.1.3 Typical countries
4. Germany
5. France
General information about the healthcare industry of
Germany, 2016e
Total health expenditure
Government's health
expenditure
OOP expenses
Medicines spending per
capita
Import
Export
General information about the healthcare industry of France,
2016e
Total health expenditure
Government's health
expenditure
OOP expenses
Medicines spending per
capita
Import
Export
Content is intentionally removed for demo purpose
35
Company General information
Source: VIRAC, igeahub
USD billion
2. Pharmaceutical Industry Overview
2.1 Global Pharmaceutical Industry – 2.1.4 Top 10 typical pharmaceutical enterprises
Top 10 pharmaceutical enterprises with largest revenue, 2017
Content is intentionally removed for demo purpose
36
2. Pharmaceutical Industry Overview
2.1 Global Pharmaceutical Industry – 2.1.4 Top 10 typical pharmaceutical enterprises
Content is intentionally removed for demo purpose
37
2. Pharmaceutical Industry Overview
2.1 Global Pharmaceutical Industry
2.2 Vietnam Pharmaceutical Industry Overview
2.3 Risks and challenges
2.4 Industry planning
2.5 Driving forces and forecast
Content
38
Northern domination before 1858,
From 1858, during the French colonial period,
1946 - 1954 resistance war against France,
1954 – 1975,
After 1975,
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.1 History of Vietnam Pharmaceutical Industry
2005
1990
Content is intentionally removed for demo purpose
39
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.2 Industry Position
Content is intentionally removed for demo purpose
40
Classification by ownership:
Classification by product segment:
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.3 Industry Scale and Feature
Content is intentionally removed for demo purpose
41
Classification of medicine markets by distribution methods Classification of medicine markets by ownership
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.3 Industry Scale and Feature
Source: VIRAC, Hanoi University of Medicine and Pharmacy
Content is intentionally removed for demo purpose
42
Hà Nội
Hoàng Sa
Trường Sa
Nam Định
Đồng NaiHồ Chí Minh
An Giang
Phú Yên
Khánh Hòa
Bắc Ninh
Tiền Giang
Đồng Tháp
Cà Mau
Hải Phòng
Bình Định
Bình Phước
Bến Tre
Thanh Hóa
Cần Thơ
Hưng Yên
Source: VIRAC
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.3 Industry Scale and Feature
Content is intentionally removed for demo purpose
43
Value chain of Vietnam pharmaceutical industry
Source: VIRAC
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.4 Value chain of the industry
Content is intentionally removed for demo purpose
44
Classification of pharmaceutical materials :
Sort by origin:
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.5 Raw materials
Content is intentionally removed for demo purpose
45
Pharmaceutical materials imports in 2012 tended to increase sharply,
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.5 Raw materials
The dependence almost entirely on the supply of pharmaceutical materials from foreign countries has made enterprises lose control of production
activities, lack of competitiveness and quality of drugs is not as expected.
Source: VIRAC, GDVC
Pharmaceutical materials imports, 2012 – 3M/2018e
USD million
Content is intentionally removed for demo purpose
46
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.5 Raw materials
Pharmaceutical materials imports, 3M/2017 – 3M/2018eUSD million
Source: VIRAC, GDVC
Content is intentionally removed for demo purpose
47
Currently 50% of machinery and equipment for pharmaceutical
production is from imported sources.
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.6 Production technology
Company
Origin
Origin of machinery and equipments of a number of large
pharmaceutical companies
Source: VIRAC
No Name of machineYear in
useOrigin Price
Source: VIRAC
Some major machineries in pharmaceutical manufacturing line
Content is intentionally removed for demo purpose
48
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.6 Production technology
Content is intentionally removed for demo purpose
49
Source: VIRAC, igeahub
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.7 R&D
Ratio of R&D/revenue at major pharmaceutical companies in the world, 2016
Content is intentionally removed for demo purpose
50
In fact, medicine companies in Vietnam are facing many difficulties in funding investment in research and development, technical staff and equipment of
high quality which has not met the requirements yet.
Outsourcing
Franchising
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.8 Production
Content is intentionally removed for demo purpose
51
Source: VIRAC, DAV
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.8 Production
It is estimated that in 2017, domestic pharmaceutical production value reached USD 2.5 billion, up 12.0% over the same period in 2016. Generally,
domestic pharmaceutical production has been increasing steadily over the years with a CAGR of FY2010 - 2017e of 15%.
USD billion
Domestic pharmaceutical production value, 2010 - 2017e
Content is intentionally removed for demo purpose
52
Source: VIRAC, GSO
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.8 Production
Product name Unit 2013 2014 2015e 2016 2017 3M/2018e
Medicine production by type, 2013 – 3M/2018e
Content is intentionally removed for demo purpose
53
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.9 Consumption
Pharmaceutical market value, 2010 – 2017e
USD billion
Source: VIRAC, DAV
The pharmaceutical industry is growing at a compound annual
growth rate (CAGR) of 17.4% for the period 2010 - 2017e. Causes
are:
Content is intentionally removed for demo purpose
54
The pharmaceutical industry in Vietnam is still considered relatively
young compared to the global industry.
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.9 Consumption
Source: VIRAC, DAV
Value ratio of domestically produced medicines in Vietnam,
2010 – 2017e
Content is intentionally removed for demo purpose
55
According to data from the General Statistics Office, the amount of pharmaceuticals consumed domestically focused on drugs containing penicillin or
antibiotics, drugs containing hormones and vitamins. Drugs like serum and vaccines are domestically consumed at a very small number. Causes leading to
this:
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.9 Consumption
Source: VIRAC, GSO
VND trillion
Domestically produced medicine consumption, 2010 - 2017e
Content is intentionally removed for demo purpose
56
Source: VIRAC, DAV, StatistaSource: VIRAC, DAV
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.9 Consumption
Spending on medicines in Vietnam, 2009 – 2017e
USD/person/year
Spending on medicines per capita in some countries, 2016e
Content is intentionally removed for demo purpose
57
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.9 Consumption
Source: VIRAC, DAV
Pharmaceuticals are distributed throughout the country through two
distribution channels through the hospital (prescribed) or through the
drug stores (not prescribed).
Source: VIRAC, DAV
Medicines consumption structure by channel, 2010 - 2017e
Current status of Patented and Generic drugs, 2010 - 2017e
Content is intentionally removed for demo purpose
58
Market data for prescription and non-prescription medicines is unclear
because there is a lack of clear distinction between these two forms of sales. USD billion
Source: VIRAC, DAV
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.9 Consumption - ETC market
Market value of prescription drugs (ETC), 2011 – 2017e
Content is intentionally removed for demo purpose
59
The OTC market has experienced relatively strong growth in value over the
past few years.
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.9 Consumption - OTC market
Market value of non-presciption drugs (OTC), 2010 – 2017eUSD billion
Source: VIRAC, DAV
Content is intentionally removed for demo purpose
60
The market value of patented drugs in Vietnam is on the upward trend but
still lower than that of the whole industry.
Distribution cost also plays an important role in determining medicine prices.
Source: VIRAC, DAV
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.9 Consumption - Patented drugs
USD billion
Patened drugs (Patent), 2010 – 2017e
Content is intentionally removed for demo purpose
61
Source: VIRAC, DAV
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.9 Consumption - Generic drugs
USD billion
Generic drug market, 2010 – 2017e
Content is intentionally removed for demo purpose
62
Vietnam pharmaceutical industry mostly depends on imported sources
with the total value of over USD 2 billion each year, moreover, in 2017,
Vietnam imported more than USD 2.8 billion, an increase of 10%
compared to the previous year.
Source: VIRAC, GDVC
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.10 Export – Import
USD million
Source: VIRAC, GDVC
Pharmaceutical imports, 2012 – 3M/2018e
Pharmaceutical imports, 3M/2017 – 3M/2018e
USD million
Content is intentionally removed for demo purpose
63
Source: VIRAC, GDVC
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.10 Export – Import
Top importing enterprises *, 3M/2018
Source: VIRAC, GDVC
Vietnam’s top import partners, 3M/2018
No. Partners Importing enterprises
* Only HS 3003 and 3004
* Only HS 3003 and 3004
Content is intentionally removed for demo purpose
64
However, Vietnam pharmaceutical industry is less competitive than
others:
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.10 Export – Import
Source: VIRAC, UN Comtrade, GDVC
Pharmaceutical exports, 2012 – 3M/2018
Content is intentionally removed for demo purpose
65
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.10 Export – Import
Top exporting enterprises, 3M/2018
Source: VIRAC, GDVC
Source: VIRAC, GDVC
No. Exporting enterprises
Export structure by country, 3M/2018
Content is intentionally removed for demo purpose
66
Source: VIRAC, DAV
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.11 Price movement
Rate of drug re-price (increase), 2013 - 2016
Content is intentionally removed for demo purpose
67
Price movements of some major drugs in the market, 12/2016 – 3/2018Unit: 1,000 VND
Source: VIRAC, Agency for Price
Management
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.11 Price movement
No Drugs Unit Manufacturer 3/2017 6/2017 9/2017 12/2017 3/2018
Compared
to the
beginning
of the
same
period
Content is intentionally removed for demo purpose
68
Type of drugLong Chau
drug store
Yen Trang
drug storeDifference
Source: VIRAC
There is a huge difference in drug prices listed at Ministry of Health and the
ones distributed to customers.
The difference in the price of some drugs at some drug stores, 2017
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.11 Price movements
Unit: VND thousand
Content is intentionally removed for demo purpose
69
Drugs distribution network in Vietnam
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.12 Distribution system
Source: VIRAC
Content is intentionally removed for demo purpose
70
The distribution system in Vietnam includes these main components:
1. Professional pharmaceutical distribution enterprises
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.12 Distribution system
Top pharmaceuticals distribution enterprise by revenue, 2016
Source: VIRAC
Content is intentionally removed for demo purpose
71
2. Pharmaceutical companies producing along with distributing
3. The wholesale market system
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.12 Distribution system
Content is intentionally removed for demo purpose
72
44. Public and private hospitals system
5.The private clinics system
Source: VIRAC, GSO
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.12 Distribution system
The number of medical facilities, 2010 - 2016
Unit: number of facilities
Excluding private-owned ones
Content is intentionally removed for demo purpose
73
6. Drug stores system:
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.12 Distribution system
Content is intentionally removed for demo purpose
74
2. Pharmaceutical Industry Overview
2.2 Vietnam Pharmaceutical Industry Overview – 2.2.12. Distribution System
Chain LogoNumber of
storesArea
Typical chain of pharmacies, 2016
Source: VIRAC
VND billion
Source: VIRAC
Outstanding distribution chain business results, 2016
Content is intentionally removed for demo purpose
75
2. Pharmaceutical Industry Overview
2.1 Global Pharmaceutical Industry
2.2 Vietnam Pharmaceutical Industry Overview
2.3 Risks and challenges
2.4 Industry planning
2.5 Driving forces and forecast
Content
76
Pharmaceutical industry is among the industries that are mostly under the management of the State.
2. Pharmaceutical Industry Overview
2.3 Risks and challenges – 2.3.1 Legal risks
Content is intentionally removed for demo purpose
77
Material risk
2. Pharmaceutical Industry Overview
2.3 Risks and challenges– 2.3.2 Industry Risks
Content is intentionally removed for demo purpose
78
2. Pharmaceutical Industry Overview
2.3 Risks and challenges – 2.3.2 Industry Risks
Content is intentionally removed for demo purpose
Market risks
Competitive risks
The risks on products and technology
79
Investment risk and failure in research and development
2. Pharmaceutical Industry Overview
2.3 Risks and Challenges – 2.3.2. Industry Risks
Average cost of R&D to produce new drugs (USD million)
Source: VIRAC, Innothink
Exchange rate risk
Content is intentionally removed for demo purpose
80
Source: VIRAC, DAV
2. Pharmaceutical Industry Overview
2.3 Risks and challenges – 2.3.3 Challenges
Unqualified sample ratio, 2010 – 2016e
Content is intentionally removed for demo purpose
81
2. Pharmaceutical Industry Overview
2.3 Risks and challenges – 2.3.3 Challenges
Content is intentionally removed for demo purpose
82
2. Pharmaceutical Industry Overview
2.1 Global Pharmaceutical Industry
2.2 Vietnam Pharmaceutical Industry Overview
2.3 Risks and challenges
2.4 Industry planning
2.5 Driving forces and forecast
Content
83
2. Pharmaceutical Industry Overview
2.4 Industry planning
Content is intentionally removed for demo purpose
84
2. Pharmaceutical Industry Overview
2.1 Global Pharmaceutical Industry
2.2 Vietnam Pharmaceutical Industry Overview
2.3 Risks and challenges
2.4 Industry planning
2.5 Driving forces and forecast
Content
85
Subsidy policy of the State
Policy to increase domestic drug spending
Extension policy of the national health insurance system
Impact from world economic agreements
2. Pharmaceutical Industry Overview
2.5 Driving forces and forecast – Driving forces
Content is intentionally removed for demo purpose
86
Population motivation and healthcare awareness:
Source: VIRAC, WHO
2. Industry Overview
2.5. Driving Forces and Forecast – Driving Forces
USD million
Total healthcare expenses, 2010 – 2016f
Source: VIRAC, IMS health
Million people
Over-60 population growth in the world, 1950 – 2050
Source: VIRAC, GSO
Population tower, 2016
Content is intentionally removed for demo purpose
87
Patents in the field of pharmaceuticals and medicine research require not only a long period but also a proper investment. Co-operation in drug research
and development not only minimizes costs but also improves the chances of successful drug testing.
Hitech pharmaceuticals
2. Pharmaceutical Industry Overview
2.5 Driving forces and forecast – Industry development trend
Content is intentionally removed for demo purpose
88
2. Pharmaceutical Industry Overview
2.5 Driving forces and forecast – Global M&A trend
Source: VIRAC, EvaluatePharma
M&A of pharmaceutical industry, 2010 - 2016
Content is intentionally removed for demo purpose
89
2. Pharmaceutical Industry Overview
2.5 Driving forces and forecast – M&A trend in Vietnam
Content is intentionally removed for demo purpose
90
Country Growth rate Generic development trends have been seen during the past year as the
FDA tried to expand its market development.
Source: VIRAC, IMS health
2. Pharmaceutical Industry Overview
2.5 Driving forces and forecast – Forecast for Global Pharmaceutical Industry
Content is intentionally removed for demo purpose
91
The increase of specific medicines
Drug USD
billionDrug
USD
billion
The revenue of top drugs in developed countries, 2018 The revenue of top drugs in developing countries, 2018
Source: VIRAC, IMS health Source: VIRAC, IMS health
2. Pharmaceutical Industry Overview
2.5 Driving forces and forecast – Forecast for Global Pharmaceutical Industry
Content is intentionally removed for demo purpose
92
The trend of VND/USD exchange rate in the coming time will continue to increase, which will affect the prices as well as sales of the pharmaceutical
industry when both pharmaceuticals and raw materials are imported.
2. Pharmaceutical Industry Overview
2.5 Driving forces and forecast – Forecast for Vietnam pharmaceutical industry
Content is intentionally removed for demo purpose
93
Source: VIRAC
2. Pharmaceutical Industry Overview
2.5 Driving forces and forecast – Forecast for Vietnam pharmaceutical industry
USD billion
The growth of total drug consumption and average drug spending per capita,
2010-2020f
Content is intentionally removed for demo purpose
94
3. Enterprise analysis
3.1 Profitability
3.2 Cost structure
3.3 Asset Management Ratios
3.4 Capital Structure
3.5 Solvency
3.6 Return on Investment
Content
3. Enterprise analysis
10 typical pharmaceutical enterprises in 2017
95
No. CompanyBusiness
sector
Revenue
(VND
billion)
Main features
1
DHG
Pharmaceuti
cal Joint
Stock
Company
2
TRAPHACO
Joint Stock
Company
3
Domesco
Medical
Import
Export JSC
4
Imexpharm
Pharmaceut
ical JSC
5
OPC
Pharmaceut
ical JSC
10 typical pharmaceutical enterprises in 2017
Source: VIRAC
Content is intentionally removed for demo purpose
3. Enterprise analysis
10 typical pharmaceutical enterprises in 2017
96
No. Company
Busine
ss
sector
Revenue
(VND
billion)
Main features
6 S.P.M JSC
7
Vimedimex
Medi – Pharma
JSC
8
Ha Tay
Pharmaceutical
JSC
9
Ben Tre
Pharmaceutical
JSC
10
Lam Dong
Pharmaceutical
JSC
Source: VIRAC
Content is intentionally removed for demo purpose
97
3. Enterprise analysis
3.1 Profitability
3.2 Cost structure
3.3 Asset Management Ratios
3.4 Capital Structure
3.5 Solvency
3.6 Return on Investment
Content
3. Enterprise analysis
3.1 Profitability
98
Profitability, 2016 - 2017
VND billion
Source: VIRAC
Content is intentionally removed for demo purpose
100
3. Enterprise analysis
3.1 Profitability
Source: VIRAC
COGS/NR, 2016 - 2017
Content is intentionally removed for demo purpose
101
3. Enterprise analysis
3.1 Profitability
3.2 Cost structure
3.3 Asset Management Ratios
3.4 Capital Structure
3.5 Solvency
3.6 Return on Investment
Content
102
3. Enterprise analysis
3.2 Cost structure
Source: VIRAC
Selling expenses, 2016 - 2017
Content is intentionally removed for demo purpose
103
3. Enterprise analysis
3.2 Cost structure
Source: VIRAC
Administrative expenses, 2016 - 2017
Content is intentionally removed for demo purpose
104
3. Enterprise analysis
3.1 Profitability
3.2 Cost structure
3.3 Asset Management Ratios
3.4 Capital Structure
3.5 Solvency
3.6 Return on Investment
Content
105
3. Enterprise analysis
3.3 Asset Management Ratios
Day
Source: VIRAC
Days in inventory, 2016 - 2017
Content is intentionally removed for demo purpose
106
3. Enterprise analysis
3.3 Asset Management Ratios
Day
Source: VIRAC
Days of sales outstanding, 2016 -2017
Content is intentionally removed for demo purpose
107
3. Enterprise analysis
3.3 Asset Management Ratios
Source: VIRAC
Asset turnover
Content is intentionally removed for demo purpose
108
3. Enterprise analysis
3.1 Profitability
3.2 Cost structure
3.3 Asset Management Ratios
3.4 Capital Structure
3.5 Solvency
3.6 Return on Investment
Content
109
3. Enterprise analysis
3.4 Capital Structure
Source: VIRAC
Self-financing ratio, 2016 - 2017
Content is intentionally removed for demo purpose
110
3. Enterprise analysis
3.1 Profitability
3.2 Cost structure
3.3 Asset Management Ratios
3.4 Capital Structure
3.5 Solvency
3.6 Return on Investment
Content
111
Solvency, 2016 - 2017
Source: VIRAC
3. Enterprise analysis
3.5 Solvency
Content is intentionally removed for demo purpose
112
3. Enterprise analysis
3.1 Profitability
3.2 Cost structure
3.3 Asset Management Ratios
3.4 Capital Structure
3.5 Solvency
3.6 Return on Investment
Content
113
3. Enterprise analysis
3.6 Return on Investment
Profit ratio, 2016 - 2017
Source: VIRAC
Content is intentionally removed for demo purpose
115
DHG Pharmaceutical Joint Stock Company
BALANCE SHEET
Unit: VND 2016 2017
A. SHORT-TERM ASSETS
I. Cash and cash equivalents
II. Short-term financial investments
III. Short-term receivables
1. Short-term receivables of customers
IV. Inventories
B. LONG-TERM ASSETS
1. Long-term receivables
2. Fixed assets
TOTAL ASSETS
A. LIABILITIES
I. Current liabilities
1. Short-term borrowings and liabilities
2. Taxes and other payables to the State budget
II. Long-term Liabilities
1. Long-term borrowings and liabilities
2. Provision for long-term payables
B. OWNER’S EQUITY
TOTAL CAPITAL RESOURCES
INCOME STATEMENT
Unit: VND 2016 2017
Net revenue from goods sold and services provided
Cost of goods sold and services provided
Gross profit of goods sold and services provided
Revenue from financing activities
Financial expenses
Interest expenses
Selling expenses
Administrative expenses
Net profit from business operations
Total accounting profit before tax
Costs of current corporate income tax
Costs of deferred corporate income tax
Profit after tax
CASH FLOW STATEMENT
Unit: VND 2016 2017
I. Cash Flow From Operating Activities
Depreciation of fixed assets
Unrealized foreign exchange gain (loss)
Net Cash Flow From Operations
II. Cash flow from investing activities
Expenditures on purchase and construction of fixed assets
and long-term assets
Net cash flow from investing activities
III. Cash flow from financing activities
Net cash flow from financing activities
Effect of foreign exchange differences
Net cash flow during the fiscal year
4. Appendix
Financial statements
Content is intentionally removed for demo purpose
116
4. Appendix
Financial statements
TRAPHACO Joint Stock Company
BALANCE SHEET
Unit: VND 2016 2017
A. SHORT-TERM ASSETS
I. Cash and cash equivalents
II. Short-term financial investments
III. Short-term receivables
1. Short-term receivables of customers
IV. Inventories
B. LONG-TERM ASSETS
1. Long-term receivables
2. Fixed assets
TOTAL ASSETS
A. LIABILITIES
I. Current liabilities
1. Short-term borrowings and liabilities
2. Taxes and other payables to the State budget
II. Long-term Liabilities
1. Long-term borrowings and liabilities
2. Provision for long-term payables
B. OWNER’S EQUITY
TOTAL CAPITAL RESOURCES
INCOME STATEMENT
Unit: VND 2016 2017
Net revenue from goods sold and services provided
Cost of goods sold and services provided
Gross profit of goods sold and services provided
Revenue from financing activities
Financial expenses
Interest expenses
Selling expenses
Administrative expenses
Net profit from business operations
Total accounting profit before tax
Costs of current corporate income tax
Costs of deferred corporate income tax
Profit after tax
CASH FLOW STATEMENT
Unit: VND 2016 2017
I. Cash Flow From Operating Activities
Depreciation of fixed assets
Unrealized foreign exchange gain (loss)
Net Cash Flow From Operations
II. Cash flow from investing activities
Expenditures on purchase and construction of fixed assets
and long-term assets
Net cash flow from investing activities
III. Cash flow from financing activities
Net cash flow from financing activities
Effect of foreign exchange differences
Net cash flow during the fiscal year
Content is intentionally removed for demo purpose
117
4. Appendix
Financial statements
CTCP Xuất Import Y Tế Domesco
BALANCE SHEET
Unit: VND 2016 2017
A. SHORT-TERM ASSETS
I. Cash and cash equivalents
II. Short-term financial investments
III. Short-term receivables
1. Short-term receivables of customers
IV. Inventories
B. LONG-TERM ASSETS
1. Long-term receivables
2. Fixed assets
TOTAL ASSETS
A. LIABILITIES
I. Current liabilities
1. Short-term borrowings and liabilities
2. Taxes and other payables to the State budget
II. Long-term Liabilities
1. Long-term borrowings and liabilities
2. Provision for long-term payables
B. OWNER’S EQUITY
TOTAL CAPITAL RESOURCES
INCOME STATEMENT
Unit: VND 2016 2017
Net revenue from goods sold and services provided
Cost of goods sold and services provided
Gross profit of goods sold and services provided
Revenue from financing activities
Financial expenses
Interest expenses
Selling expenses
Administrative expenses
Net profit from business operations
Total accounting profit before tax
Costs of current corporate income tax
Costs of deferred corporate income tax
Profit after tax
CASH FLOW STATEMENT
Unit: VND 2016 2017
I. Cash Flow From Operating Activities
Depreciation of fixed assets
Unrealized foreign exchange gain (loss)
Net Cash Flow From Operations
II. Cash flow from investing activities
Expenditures on purchase and construction of fixed assets
and long-term assets
Net cash flow from investing activities
III. Cash flow from financing activities
Net cash flow from financing activities
Effect of foreign exchange differences
Net cash flow during the fiscal year
Content is intentionally removed for demo purpose
118
4. Appendix
Financial statements
Imexpharm Pharmaceutical JSC
BALANCE SHEET
Unit: VND 2016 2017
A. SHORT-TERM ASSETS
I. Cash and cash equivalents
II. Short-term financial investments
III. Short-term receivables
1. Short-term receivables of customers
IV. Inventories
B. LONG-TERM ASSETS
1. Long-term receivables
2. Fixed assets
TOTAL ASSETS
A. LIABILITIES
I. Current liabilities
1. Short-term borrowings and liabilities
2. Taxes and other payables to the State budget
II. Long-term Liabilities
1. Long-term borrowings and liabilities
2. Provision for long-term payables
B. OWNER’S EQUITY
TOTAL CAPITAL RESOURCES
INCOME STATEMENT
Unit: VND 2016 2017
Net revenue from goods sold and services provided
Cost of goods sold and services provided
Gross profit of goods sold and services provided
Revenue from financing activities
Financial expenses
Interest expenses
Selling expenses
Administrative expenses
Net profit from business operations
Total accounting profit before tax
Costs of current corporate income tax
Costs of deferred corporate income tax
Profit after tax
CASH FLOW STATEMENT
Unit: VND 2016 2017
I. Cash Flow From Operating Activities
Depreciation of fixed assets
Unrealized foreign exchange gain (loss)
Net Cash Flow From Operations
II. Cash flow from investing activities
Expenditures on purchase and construction of fixed assets
and long-term assets
Net cash flow from investing activities
III. Cash flow from financing activities
Net cash flow from financing activities
Effect of foreign exchange differences
Net cash flow during the fiscal year
Content is intentionally removed for demo purpose
119
4. Appendix
Financial statements
OPC Pharmaceutical JSC
BALANCE SHEET
Unit: VND 2016 2017
A. SHORT-TERM ASSETS
I. Cash and cash equivalents
II. Short-term financial investments
III. Short-term receivables
1. Short-term receivables of customers
IV. Inventories
B. LONG-TERM ASSETS
1. Long-term receivables
2. Fixed assets
TOTAL ASSETS
A. LIABILITIES
I. Current liabilities
1. Short-term borrowings and liabilities
2. Taxes and other payables to the State budget
II. Long-term Liabilities
1. Long-term borrowings and liabilities
2. Provision for long-term payables
B. OWNER’S EQUITY
TOTAL CAPITAL RESOURCES
INCOME STATEMENT
Unit: VND 2016 2017
Net revenue from goods sold and services provided
Cost of goods sold and services provided
Gross profit of goods sold and services provided
Revenue from financing activities
Financial expenses
Interest expenses
Selling expenses
Administrative expenses
Net profit from business operations
Total accounting profit before tax
Costs of current corporate income tax
Costs of deferred corporate income tax
Profit after tax
CASH FLOW STATEMENT
Unit: VND 2016 2017
I. Cash Flow From Operating Activities
Depreciation of fixed assets
Unrealized foreign exchange gain (loss)
Net Cash Flow From Operations
II. Cash flow from investing activities
Expenditures on purchase and construction of fixed assets
and long-term assets
Net cash flow from investing activities
III. Cash flow from financing activities
Net cash flow from financing activities
Effect of foreign exchange differences
Net cash flow during the fiscal year
Content is intentionally removed for demo purpose
120
4. Appendix
Financial statements
S.P.M JSC
BALANCE SHEET
Unit: VND 2016 2017
A. SHORT-TERM ASSETS
I. Cash and cash equivalents
II. Short-term financial investments
III. Short-term receivables
1. Short-term receivables of customers
IV. Inventories
B. LONG-TERM ASSETS
1. Long-term receivables
2. Fixed assets
TOTAL ASSETS
A. LIABILITIES
I. Current liabilities
1. Short-term borrowings and liabilities
2. Taxes and other payables to the State budget
II. Long-term Liabilities
1. Long-term borrowings and liabilities
2. Provision for long-term payables
B. OWNER’S EQUITY
TOTAL CAPITAL RESOURCES
INCOME STATEMENT
Unit: VND 2016 2017
Net revenue from goods sold and services provided
Cost of goods sold and services provided
Gross profit of goods sold and services provided
Revenue from financing activities
Financial expenses
Interest expenses
Selling expenses
Administrative expenses
Net profit from business operations
Total accounting profit before tax
Costs of current corporate income tax
Costs of deferred corporate income tax
Profit after tax
CASH FLOW STATEMENT
Unit: VND 2016 2017
I. Cash Flow From Operating Activities
Depreciation of fixed assets
Unrealized foreign exchange gain (loss)
Net Cash Flow From Operations
II. Cash flow from investing activities
Expenditures on purchase and construction of fixed assets
and long-term assets
Net cash flow from investing activities
III. Cash flow from financing activities
Net cash flow from financing activities
Effect of foreign exchange differences
Net cash flow during the fiscal year
Content is intentionally removed for demo purpose
121
4. Appendix
Financial statements
Vimedimex Medi – Pharma JSC
BALANCE SHEET
Unit: VND 2016 2017
A. SHORT-TERM ASSETS
I. Cash and cash equivalents
II. Short-term financial investments
III. Short-term receivables
1. Short-term receivables of customers
IV. Inventories
B. LONG-TERM ASSETS
1. Long-term receivables
2. Fixed assets
TOTAL ASSETS
A. LIABILITIES
I. Current liabilities
1. Short-term borrowings and liabilities
2. Taxes and other payables to the State budget
II. Long-term Liabilities
1. Long-term borrowings and liabilities
2. Provision for long-term payables
B. OWNER’S EQUITY
TOTAL CAPITAL RESOURCES
INCOME STATEMENT
Unit: VND 2016 2017
Net revenue from goods sold and services provided
Cost of goods sold and services provided
Gross profit of goods sold and services provided
Revenue from financing activities
Financial expenses
Interest expenses
Selling expenses
Administrative expenses
Net profit from business operations
Total accounting profit before tax
Costs of current corporate income tax
Costs of deferred corporate income tax
Profit after tax
CASH FLOW STATEMENT
Unit: VND 2016 2017
I. Cash Flow From Operating Activities
Depreciation of fixed assets
Unrealized foreign exchange gain (loss)
Net Cash Flow From Operations
II. Cash flow from investing activities
Expenditures on purchase and construction of fixed assets
and long-term assets
Net cash flow from investing activities
III. Cash flow from financing activities
Net cash flow from financing activities
Effect of foreign exchange differences
Net cash flow during the fiscal year
Content is intentionally removed for demo purpose
122
4. Appendix
Financial statements
Ha Tay Pharmaceutical JSC
BALANCE SHEET
Unit: VND 2016 2017
A. SHORT-TERM ASSETS
I. Cash and cash equivalents
II. Short-term financial investments
III. Short-term receivables
1. Short-term receivables of customers
IV. Inventories
B. LONG-TERM ASSETS
1. Long-term receivables
2. Fixed assets
TOTAL ASSETS
A. LIABILITIES
I. Current liabilities
1. Short-term borrowings and liabilities
2. Taxes and other payables to the State budget
II. Long-term Liabilities
1. Long-term borrowings and liabilities
2. Provision for long-term payables
B. OWNER’S EQUITY
TOTAL CAPITAL RESOURCES
INCOME STATEMENT
Unit: VND 2016 2017
Net revenue from goods sold and services provided
Cost of goods sold and services provided
Gross profit of goods sold and services provided
Revenue from financing activities
Financial expenses
Interest expenses
Selling expenses
Administrative expenses
Net profit from business operations
Total accounting profit before tax
Costs of current corporate income tax
Costs of deferred corporate income tax
Profit after tax
CASH FLOW STATEMENT
Unit: VND 2016 2017
I. Cash Flow From Operating Activities
Depreciation of fixed assets
Unrealized foreign exchange gain (loss)
Net Cash Flow From Operations
II. Cash flow from investing activities
Expenditures on purchase and construction of fixed assets
and long-term assets
Net cash flow from investing activities
III. Cash flow from financing activities
Net cash flow from financing activities
Effect of foreign exchange differences
Net cash flow during the fiscal year
Content is intentionally removed for demo purpose
123
4. Appendix
Financial statements
Ben Tre Pharmaceutical JSC
BALANCE SHEET
Unit: VND 2016 2017
A. SHORT-TERM ASSETS
I. Cash and cash equivalents
II. Short-term financial investments
III. Short-term receivables
1. Short-term receivables of customers
IV. Inventories
B. LONG-TERM ASSETS
1. Long-term receivables
2. Fixed assets
TOTAL ASSETS
A. LIABILITIES
I. Current liabilities
1. Short-term borrowings and liabilities
2. Taxes and other payables to the State budget
II. Long-term Liabilities
1. Long-term borrowings and liabilities
2. Provision for long-term payables
B. OWNER’S EQUITY
TOTAL CAPITAL RESOURCES
INCOME STATEMENT
Unit: VND 2016 2017
Net revenue from goods sold and services provided
Cost of goods sold and services provided
Gross profit of goods sold and services provided
Revenue from financing activities
Financial expenses
Interest expenses
Selling expenses
Administrative expenses
Net profit from business operations
Total accounting profit before tax
Costs of current corporate income tax
Costs of deferred corporate income tax
Profit after tax
CASH FLOW STATEMENT
Unit: VND 2016 2017
I. Cash Flow From Operating Activities
Depreciation of fixed assets
Unrealized foreign exchange gain (loss)
Net Cash Flow From Operations
II. Cash flow from investing activities
Expenditures on purchase and construction of fixed assets
and long-term assets
Net cash flow from investing activities
III. Cash flow from financing activities
Net cash flow from financing activities
Effect of foreign exchange differences
Net cash flow during the fiscal year
Content is intentionally removed for demo purpose
124
4. Appendix
Financial statements
Lam Dong Pharmaceutical JSC
BALANCE SHEET
Unit: VND 2016 2017
A. SHORT-TERM ASSETS
I. Cash and cash equivalents
II. Short-term financial investments
III. Short-term receivables
1. Short-term receivables of customers
IV. Inventories
B. LONG-TERM ASSETS
1. Long-term receivables
2. Fixed assets
TOTAL ASSETS
A. LIABILITIES
I. Current liabilities
1. Short-term borrowings and liabilities
2. Taxes and other payables to the State budget
II. Long-term Liabilities
1. Long-term borrowings and liabilities
2. Provision for long-term payables
B. OWNER’S EQUITY
TOTAL CAPITAL RESOURCES
INCOME STATEMENT
Unit: VND 2016 2017
Net revenue from goods sold and services provided
Cost of goods sold and services provided
Gross profit of goods sold and services provided
Revenue from financing activities
Financial expenses
Interest expenses
Selling expenses
Administrative expenses
Net profit from business operations
Total accounting profit before tax
Costs of current corporate income tax
Costs of deferred corporate income tax
Profit after tax
CASH FLOW STATEMENT
Unit: VND 2016 2017
I. Cash Flow From Operating Activities
Depreciation of fixed assets
Unrealized foreign exchange gain (loss)
Net Cash Flow From Operations
II. Cash flow from investing activities
Expenditures on purchase and construction of fixed assets
and long-term assets
Net cash flow from investing activities
III. Cash flow from financing activities
Net cash flow from financing activities
Effect of foreign exchange differences
Net cash flow during the fiscal year
Content is intentionally removed for demo purpose
REPORT DISCLAIMER
REPORT DISCLAIMER
This document has been prepared in good faith on the basis of information available at the date of publication without any
independent verification. VIRAC has produced this report for private circulation to professional clients only. All information and
statistical data herein have been obtained from sources we believe to be reliable and made to ensure the accuracy of the contents of
the pages of the report at the time of preparation. Such information has not been independently verified and VIRAC makes no
representation or warranty, whether express or implied, of any kind with respect to the document and its contents, information and
materials. The content found in this report is proprietary to VIRAC and is provided solely for your personal and non-commercial use.
You agree that you will not use this report for any purpose that is unlawful and that you will not reproduce the report or redistribute it
outside your organisation, or place it on a website for public access without the express written permission of VIRAC.
SHOULD YOU NEED ANY ASSISTANCE, PLEASE CONTACT US:
VIETNAM INDUSTRY RESEARCH AND CONSULTANCY (VIRAC JSC.,)
6th Floor, Anh Minh Building, 36 Hoang Cau, O Cho Dua, Dong Da, Hanoi, Vietnam
Website: http://virac.com.vn/
Email: [email protected] | Tel: +84 463289520
123